Abstract:
:Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter duration of survival, compared with 42 cases of malignant lymphoma of the same anatomical region but without angiocentric lesions. Patients with angiocentric lymphoma were associated with other bad prognostic factors such as elevated levels of lactic dehydrogenase and beta 2 microglobulin, local bone destruction and lymphopenia. Immunophenotyping studies showed that most patients with angiocentric lesions had T cell lymphomas (18 of 23, 78 per cent). We believe that patients with angiocentric T cell lymphomas of the nose, paranasal sinuses and hard palate represent a distinctive clinico-pathological entity with different clinical presentation and outcome. Patients with angiocentric T cell lymphomas had frequent relapse at extranodal sites and combined therapy should be considered as the initial therapeutic approach.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Aviles A,Rodriguez L,Guzman R,Talavera A,Garcia EL,Diaz-Maqueo JCdoi
10.1002/hon.2900100303subject
Has Abstractpub_date
1992-05-01 00:00:00pages
141-7issue
3-4eissn
0278-0232issn
1099-1069journal_volume
10pub_type
杂志文章abstract::Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.792
更新日期:2006-12-01 00:00:00
abstract::Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2793
更新日期:2020-08-27 00:00:00
abstract::Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900040303
更新日期:1986-07-01 00:00:00
abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900050207
更新日期:1987-04-01 00:00:00
abstract::One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080103
更新日期:1990-01-01 00:00:00
abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.991
更新日期:2011-12-01 00:00:00
abstract::There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.1020
更新日期:2012-12-01 00:00:00
abstract::Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2900090414
更新日期:1991-07-01 00:00:00
abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900030106
更新日期:1985-01-01 00:00:00
abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080303
更新日期:1990-05-01 00:00:00
abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2092
更新日期:2014-06-01 00:00:00
abstract::To clarify the origin of Hodgkin (H) and Sternberg-Reed (SR) cells, frozen sections of lymph nodes from 30 patients with Hodgkin's disease were immunostained with a large panel of monoclonal antibodies reactive with cells of lymphoid tissue and granulopoiesis. The results showed that: (a) H and SR cells are devoid of ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900010105
更新日期:1983-01-01 00:00:00
abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2809
更新日期:2020-09-25 00:00:00
abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2298
更新日期:2017-09-01 00:00:00
abstract::There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100602
更新日期:1992-11-01 00:00:00
abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2236
更新日期:2017-03-01 00:00:00
abstract::Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.858
更新日期:2008-09-01 00:00:00
abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2192
更新日期:2016-06-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2729
更新日期:2020-08-01 00:00:00
abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120304
更新日期:1994-05-01 00:00:00
abstract::To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070506
更新日期:1989-09-01 00:00:00
abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2368
更新日期:2017-12-01 00:00:00
abstract::The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2504
更新日期:2018-02-27 00:00:00
abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2547
更新日期:2019-02-01 00:00:00
abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2520
更新日期:2018-10-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.1017
更新日期:2012-09-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2572
更新日期:2019-04-01 00:00:00
abstract::Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080109
更新日期:1990-01-01 00:00:00
abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2532
更新日期:2018-10-01 00:00:00